Cochrane Abstracts
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Retinoic Acid Postconsolidation Therapy for High‐risk Neuroblastoma Patients Treated With Autologous Haematopoietic Stem Cell Transplantation." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439727/all/Retinoic_acid_postconsolidation_therapy_for_high‐risk_neuroblastoma_patients_treated_with_autologous_haematopoietic_stem_cell_transplantation.
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/all/Retinoic_acid_postconsolidation_therapy_for_high‐risk_neuroblastoma_patients_treated_with_autologous_haematopoietic_stem_cell_transplantation. Accessed March 19, 2025.
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/all/Retinoic_acid_postconsolidation_therapy_for_high‐risk_neuroblastoma_patients_treated_with_autologous_haematopoietic_stem_cell_transplantation
Retinoic Acid Postconsolidation Therapy for High‐risk Neuroblastoma Patients Treated With Autologous Haematopoietic Stem Cell Transplantation [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/all/Retinoic_acid_postconsolidation_therapy_for_high‐risk_neuroblastoma_patients_treated_with_autologous_haematopoietic_stem_cell_transplantation.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
ID - 439727
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439727/all/Retinoic_acid_postconsolidation_therapy_for_high‐risk_neuroblastoma_patients_treated_with_autologous_haematopoietic_stem_cell_transplantation
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
